Approvals/TGA/BLINCYTO blinatumomab (rch) 38.5 microgram powder for injection vial with Intravenous (IV) solution stabiliser

Approved

STANDARD

BLINCYTO blinatumomab (rch) 38.5 microgram powder for injection vial with Intravenous (IV) solution stabiliser

Amgen Australia Pty Ltd🇦🇺 Therapeutic Goods Administration

Approval Id: ef237ee3781ae82a
Product Name: BLINCYTO blinatumomab (rch) 38.5 microgram powder for injection vial with Intravenous (IV) solution stabiliser
Artg Id: 232805
Artg Name: BLINCYTO blinatumomab (rch) 38.5 microgram powder for injection vial with Intravenous (IV) solution stabiliser
Sponsor: Amgen Australia Pty Ltd
Company Detail Path: /organization/amgen-australia-pty-ltd
Artg Date: 2015-11-09
Registration Type: Medicine
Therapeutic Good Type: Medicine
Licence Status: A
Licence Category: RE
Consumer Medicine Info: http://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2016-CMI-01304-1
Product Information: http://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2015-PI-02791-1

Approved

Agency

TGA

Country

🇦🇺

Approval Date

May 30, 2025

Approval ID

ef237ee3781ae82a

Type

Standard